FDA approves once-daily version of Requip XL

06/16/2008 | Bloomberg

GlaxoSmithKline PLC has received FDA approval to market a new once-daily formulation of Requip XL, a treatment for Parkinson's disease and restless legs syndrome. The new version will "provide smoother blood levels without the peaks and troughs that multiple daily doses typically deliver," a neurology expert said in the company's statement.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA